Weekly founder insights · Japan → U.S.

Clinical Evidence

Evidence that supports U.S. validation, clinical use and adoption.

For Japanese medical-device, diagnostics and regulated medical-AI founders entering the United States.

Showing the dated edition below. Weekly updates are being connected.

1. Final classification order codifying a 2023 classification · New · 2026-10-09

   Home-collected diagnostics: validate the complete testing workflow

   What changed: FDA codified Class II controls for home-collected, laboratory-tested STI nucleic-acid systems, covering prospective specimens, comparators, statistical planning, sample shipping, usability and result interpretation.

   Founder implication · interpretation: Japanese diagnostic teams need evidence across the patient-to-laboratory journey, including whether lay users collect specimens correctly.

   Next action: Define users, specimen types, shipping conditions, comparator and usability evidence before selecting collection kits or study sites.

   What to confirm: Published and effective October 9, 2026, this codifies a November 15, 2023 classification. It is not a new clearance or a blanket rule for all home diagnostics; the covered device type remains subject to 510(k).

   Primary sources:FDA / Federal Register · Home-collected STI nucleic-acid system classification
2. Final classification order codifying a 2023 classification · New · 2026-10-06

   Hereditary-cancer sequencing: map gene and variant evidence gaps

   What changed: FDA codified Class II controls for hereditary-cancer predisposition sequencing, covering specimen handling, software validation, variant interpretation and accuracy against an appropriate orthogonal method.

   Founder implication · interpretation: Japanese genomic-diagnostic teams can assess whether existing datasets cover clinically important genes, difficult variants and predefined statistical criteria.

   Next action: Map gene and variant coverage, comparator methods and confidence intervals to the controls before commissioning additional U.S. testing.

   What to confirm: The October 6, 2026 order codifies a September 29, 2023 classification. The covered device is not intended for screening, prenatal testing or stand-alone diagnosis; these controls do not establish a pathway for every cancer test.

   Primary sources:FDA / Federal Register · Hereditary-cancer DNA sequencing system classification
3. FDA paper synthesizing existing guidance · Ongoing · 2026-08-20

   Digital endpoints: connect technical performance to patient relevance

   What changed: FDA’s August paper distinguishes technical verification, analytical validation and clinical validation for digitally derived clinical-investigation outcomes, emphasizing patient relevance, usability and error sources.

   Founder implication · interpretation: Japanese wearable and AI teams need to justify what a proposed endpoint measures in the intended population.

   Next action: Document context of use, the meaningful health concept and validation evidence; seek appropriate regulatory feedback before relying on a novel endpoint.

   What to confirm: Announced August 20, 2026, this paper draws on existing guidance. It is not new marketing authorization, mandatory standalone guidance or automatic acceptance of a digital endpoint.

   Primary sources:FDA · Digitally derived measures paper overviewFDA · Digitally derived measures paper